ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: 58 years Female

Specimen Collected: 7/17/2025 09:33 MDT

High Grade B-Cell Lymphoma Reflex Panel	**Received: 7/17/2025 09:33 MDT**		**Report/Verified: 7/17/2025 09:35 MDT**
Procedure	**Result**	**Units**	**Reference Interval**
MYC FISH Reference Number	ABC 123		
MYC FISH Source	Tissue [i1]		

High Grade B-Cell Lymphoma Reflex Panel	**Received: 7/17/2025 09:33 MDT**		**Report/Verified: 7/17/2025 09:36 MDT**
Procedure	**Result**	**Units**	**Reference Interval**
MYC FISH Result	Negative [f1]		
Total Cell Count	100		
Scoring Method	Manual		

11Q Aberrations by Fish	**Received: 7/17/2025 09:33 MDT**		**Report/Verified: 7/17/2025 09:36 MDT**
Procedure	**Result**	**Units**	**Reference Interval**
11Q FISH Reference Number	ABC 123		
11Q FISH Source	Tissue		

11Q Aberrations by Fish	**Received: 7/17/2025 09:33 MDT**		**Report/Verified: 7/17/2025 10:13 MDT**
Procedure	**Result**	**Units**	**Reference Interval**
Scoring Method	Manual		
11Q FISH Result	11q Normal [f2] [i2]		
MLL Percent Gain	0	%	
MLL Total Cell Count	100		
FLI1 Percent Loss	0	%	
FLI1 Total Cell Count	100		
Doctor Review,11Q FISH	[redacted]		

Result Footnote

f1: MYC FISH Result

LSI MYC by FISH result is negative. Testing has been reflexed to 11Q FISH based on client order.

Controls were run and performed as expected.
This result has been reviewed and approved by [redacted]

f2: 11Q FISH Result

11Q aberration was NOT detected.

Controls were run and performed as expected.
This result has been reviewed and approved by [redacted]

Test Information

i1: MYC FISH Source

INTERPRETIVE INFORMATION: MYC Rearrangement, FISH

MYC fluorescence in situ hybridization (FISH) analysis is designed to detect 8q24 (MYC) translocations regardless of rearrangement partners. Differentially labeled

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Test Information

i1: MYC FISH Source

probes targeting the upstream (5') and downstream (3') flanking regions of the MYC gene were used (Agilent Technologies).

When 12 percent or more of the cells evaluated show a classic (typical) abnormal signal pattern, it is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 100 percent of MYC rearrangements in patients with MYC-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

MYC rearrangement is seen in a variety of B-cell lymphomas, including diffuse large B-cell lymphomas (DLBCL), Burkitt lymphoma, and "double hit" or "triple hit" lymphomas. Results should be correlated with clinical, morphologic, and immunophenotypic data.

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section.

The use of this assay on decalcified tissues has not been validated. Results should be interpreted with caution.

Controls performed appropriately.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i2: 11Q FISH Result

INTERPRETIVE INFORMATION: 11Q Aberrations by FISH

Fluorescence in situ hybridization (FISH) analysis was performed on sections from a paraffin embedded tissue block using differentially labeled fluorescent probes targeting the 11q23.3 (MLL), 11q24.3 (FLI1), and a chromosome 11 centromeric control region (Agilent Technologies). Cells were evaluated from regions of tumor identified on histopathologic review of a matching hematoxylin and eosin-stained section. Controls performed appropriately.

This test is designed to detect gain of the 11q23.3 (MLL) region and loss of the 11q24.3 (FLI1) region. An abnormal signal pattern seen in 25 percent or more of the evaluated tumor cells is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 95 percent of 11q aberrations in patients with High-Grade B-Cell Lymphoma with 11q aberrations,

Test Information

i2: 11Q FISH Result

except for rare instances of complex genomic changes or copy-number neutral losses of heterozygosity. Assay range and limit of detection were generated using normal and known positive cases respectively.

Identification of 11q aberrations is useful in the diagnosis of High-Grade B-Cell Lymphoma with 11q aberrations (HGBL-11q).

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.